<DOC>
	<DOCNO>NCT00850070</DOCNO>
	<brief_summary>This study intend provide definitive test hypothesis elevate sapropterin ( tetrahydrobiopterin , cofactor several key brain enzyme ) concentration CNS result measurable improvement core symptom autism young individual , age 6 year . The study entail double-blind , placebo-controlled 16-week intervention .</brief_summary>
	<brief_title>Sapropterin Treatment Autistic Disorder</brief_title>
	<detailed_description>Over past 20 year , several study suggest sapropterin ( tetrahydrobiopterin ) might ameliorate core symptom autism least young ( age 6 ) subject . However , study somewhat questionable methodology , major one dose sapropterin use roughly one tenth think need provide physiologically meaningful increase sapropterin central nervous system ( CNS ) . This study look impact sustain exposure high dose well-diagnosed young child autism .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Parents sign inform consent Child meet criteria autistic disorder ( base score Autism Diagnostic Interview—Revised ( ADIR ) Autism Diagnostic Observation Schedule ( ADOS ) , give certified administrator , research reliable ) Child Developmental Quotient ( DQ ) ≥ 50 ( Vineland Adaptive Scales , Interview Edition ) Parents agree delay initiation treatment doubleblind trial Child seizures past 6 month change seizure medication past 4 week . Child &gt; 18 point subscale ( Autism Behavior Checklist ) ABCI Child take psychoactive medication supplement , anticonvulsant , soporific ( melatonin , diphenhydramine ) Child change stand medication past 4 week . Child known genetic disorder Child know severe neurological disorder , include cerebral palsy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>autism</keyword>
</DOC>